Artivion (NYSE:AORT) Price Target Lowered to $32.00 at Needham & Company LLC

Artivion (NYSE:AORT - Free Report) had its target price trimmed by Needham & Company LLC from $34.00 to $32.00 in a research report sent to investors on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other analysts also recently weighed in on AORT. Oppenheimer raised their target price on Artivion from $30.00 to $32.00 and gave the company an "outperform" rating in a research note on Friday, November 8th. JMP Securities restated a "market outperform" rating and set a $33.00 price objective on shares of Artivion in a report on Tuesday, December 10th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Artivion presently has an average rating of "Buy" and a consensus target price of $31.40.

Artivion Trading Down 0.1 %

NYSE AORT traded down $0.02 during mid-day trading on Tuesday, reaching $25.34. 568,539 shares of the stock were exchanged, compared to its average volume of 404,014. The stock has a market capitalization of $1.06 billion, a PE ratio of -1,267.00 and a beta of 1.75. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. Artivion has a 1-year low of $18.38 and a 1-year high of $32.33. The business's fifty day simple moving average is $29.58 and its 200 day simple moving average is $27.80.

Remove Ads

Artivion (NYSE:AORT - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.51). The company had revenue of $97.31 million for the quarter, compared to analyst estimates of $100.82 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. On average, research analysts anticipate that Artivion will post 0.37 earnings per share for the current fiscal year.

Insider Transactions at Artivion

In other news, CEO James P. Mackin sold 42,156 shares of Artivion stock in a transaction on Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $1,151,280.36. Following the transaction, the chief executive officer now directly owns 663,882 shares in the company, valued at approximately $18,130,617.42. This trade represents a 5.97 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Andrew M. Green sold 7,618 shares of the firm's stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total transaction of $228,540.00. Following the transaction, the vice president now owns 33,503 shares of the company's stock, valued at approximately $1,005,090. This trade represents a 18.53 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 77,224 shares of company stock worth $2,162,330. Insiders own 8.10% of the company's stock.

Hedge Funds Weigh In On Artivion

A number of hedge funds have recently modified their holdings of AORT. Quarry LP lifted its position in shares of Artivion by 210.8% in the third quarter. Quarry LP now owns 1,209 shares of the company's stock worth $32,000 after buying an additional 820 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in shares of Artivion by 236.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock valued at $32,000 after acquiring an additional 786 shares in the last quarter. R Squared Ltd acquired a new stake in Artivion in the 4th quarter worth approximately $39,000. Arcadia Investment Management Corp MI bought a new position in shares of Artivion in the fourth quarter valued at approximately $43,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Artivion in the 4th quarter valued at $64,000. 86.37% of the stock is owned by institutional investors and hedge funds.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.